Objective: To compare the efficacy of two commercially available dentifrices (colgate total toothpaste containing triclosan and copolymer was used as the experimental and a toothpaste containing triclosan without copolymer the control) in the control of dental plaque and gingivitis. Methods: A double blind clinical study was conducted in 200 adult male and female subjects from Chengdu, China were entered into the study and stratified into two treatment groups which were balanced for age, sex, baseline of Quigley Hein plaque index scores(PI) and baseline of Loe Silness gingival index scores(GI). Subjects received an oral prophylaxis and were instructed to brush their teeth for one minute twice daily with their assigned dentifrice. Three and six months after application of the dentifrices plaque and gingivitis examinations were conducted. Results: At the end of the study, 183 subjects complied with the protocol and completed the entire six month study. Before use of the dentifrices GI in experimental and control groups was 1.63?0.36 and 1.68?0.34, it was 0.45?0.30 and 0.52?0.33 in 3 months, and 0.43?0.32 and 0.58?0.38 in 6 months( P

Objective To investigate the expression of secretagogin(SCGN) and chromogranin A(CgA) in pancreatic neuroen‐docrine tumors (PNETs) .Methods Totally 54 cases of PNETs hospitalized in our hospital from October 2007 to October 2013 were enrolled in our study .Immunohistochemical detection was used to determine secretagogin and CgA .Results Secretagogin and CgA were highly expressed in all PNETs specimens .Compared with CgA ,secretagogin were highly expressed in the non‐functional PNETs ,tumor volume>30 cm3 ,the enveloped ,vascular invasion and lymph node metastasis (P<0 .05) .There were no statistically significant difference between SCGN and CgA in functional PNETs tumor volume ≤30 cm3 ,no enveloped ,no vascular invasion and lymph node metastasis(P>0 .05) .Conclusion The expression of secretagogin and CgA in tumor combined with PNETs pathologi‐cal characteristics can predict the severity of PNETs .

Objective ToexploretheprognosticvalueoftroponinT(cTnT)concentrationinpatientswithacuterespiratorydis-tress syndrome(ARDS) .Methods 82 patients from January 2008 to June 2011 were enrolled ,and admission blood samples were obtained for cTnT measurement .A variety of clinical and laboratory variables were recorded .With 28 days as end point ,the cTnT concentration ,acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ ) score ,and Murray lung injury score(LIS) were compared respectively between survivors and non-survivors .The association between the concentration of cTnT and 28-day mortali-ty was assessed .Results 43 patients died during the 28-day observation period among 82 patients .cTnT concentration among non-survivors were significantly higher than those of survivors ,(0 .048 ± 0 .03)ng/mL vs .(0 .027 ± 0 .014)ng/mL(P<0 .01) .The con-centration of cTnT showed positive correlation with APACHE Ⅱ score and LIS(r1 =0 .509 ,r2 =0 .314 ,both P<0 .01) .cTnT con-centration had an area under the receiver operating characteristic (ROC) curve(AUC) of 0 .734 for predicting 28-day mortality ,with 95% confidence interval(95% CI) 0 .627 -0 .841 ;the optimal cTnT cut point for predicting 28-day mortality was 0 .034 ng/mL . cTnT concentration higher than 0 .034 ng/mL ,APACHE Ⅱ score higher than 17 .5 and LIS higher than 1 .65 were the independent risk factor of 28-day mortality .Conclusion cTnT concentration is an independent predictor of 28-day mortality in patients with ARDS .cTnT concentration shows a high predictive value in patients with ARDS ,similar to APACHE Ⅱ score and LIS .